This article is from the Impotence FAQ, by Sine Nomine llama@drizzle.com with numerous contributions by others.
Yes. A class-action lawsuit has been filed against Vivus by a group of
investors who say that Vivus made inflated claims about the success
rate of MUSE and thus misled them into investing in Vivus stock.
 
Continue to: